TSN 1611
Alternative Names: TSN-1611Latest Information Update: 03 Jun 2024
At a glance
- Originator Tyligand Bioscience
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 24 May 2024 Tyligand Bioscience plans a phase I/II trial for Solid tumours in China (PO) in 2024
- 30 Apr 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT06385925)
- 30 Apr 2024 NMPA approves IND application for TSN 1611 in Solid tumors in China